Ligand Pharmaceuticals Incorporated (LGND) earnings
LGND earnings moved a median of +1.05% by the close. Quarterly and annual LGND reports and results, each read against the price at its own news timestamp. Back to the LGND overview →
30 measured LGND earnings events.
Where these LGND earnings landedvs 29 measured LGND earnings reactions
| Middle 50% of LGND earnings reactions | -0.64% to +2.71% |
|---|---|
| Median reaction (to close) | +1.05% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 LGND earnings events with a measured close landed between -0.64% and +2.71%; 62% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +0.97% | — | |
| Ligand Reports Second Quarter 2026 Financial Results | Press release | +1.29% | -1.94% | |
| Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | +0.59% | +0.56% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -1.54% | -0.42% | |
| Ligand Reports First Quarter 2026 Financial Results | Press release | +6.93% | +2.60% | |
| Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | +0.00% | -0.51% | |
| Form 10-K LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.00% | +2.71% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +0.70% | +2.37% | |
| Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance | Press release | +1.02% | +6.24% | |
| Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 | Press release | -0.20% | -0.11% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +2.53% | +6.24% | |
| Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Press release | -0.99% | +1.05% | |
| Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 | Press release | -1.32% | -2.40% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | -0.42% | -1.08% | |
| Ligand Reports First Quarter 2025 Financial Results | Press release | -0.86% | -4.13% | |
| Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 | Press release | -0.65% | +2.47% | |
| Form 10-K LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | -0.41% | -8.15% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +0.39% | +1.01% | |
| Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance | Press release | -1.29% | +9.78% | |
| Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 | Press release | +0.61% | +3.84% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | +2.07% | +3.56% | |
| Ligand Reports Second Quarter 2024 Financial Results | Press release | -1.25% | -6.68% | |
| Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 | Press release | -0.49% | +0.93% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | +2.02% | +8.64% | |
| Ligand Reports First Quarter 2024 Financial Results | Press release | -1.60% | +8.05% | |
| Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 | Press release | +1.67% | +2.03% | |
| Form 10-K LIGAND PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | +0.00% | -1.69% | |
| Form 10-Q LIGAND PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | +0.40% | +1.09% | |
| Ligand Reports Third Quarter 2023 Financial Results | Press release | -6.18% | -0.64% | |
| Ligand To Report Third Quarter 2023 Financial Results On November 8 | Press release | +0.77% | +1.23% |
Keep exploring
More LGND: analyst actions → · SEC filings → · LGND overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
| Microbot Medical Inc. (MBOT) | 366 | -0.19% | 43% |
| SOPHIRIS BIO INC (SPHS) | 366 | -0.23% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.